Acne Vulgaris
Conditions
Keywords
acne vulgaris, acupuncture, cupping, ear point tapping, randomized controlled trial
Brief summary
This trial is designed to evaluate the efficacy of different frequencies in treating the moderate and severe acne vulgaris using acupuncture combined with moving cupping and ear point tapping.
Detailed description
Background: Acne vulgaris is a common skin disease, especially in adolescents and young adults. Acne affects approximately 85% of teenagers, but can occur in most age groups and can persist into adulthood. There is no mortality associated with acne, but there is often significant physical and psychological morbidity. Acupuncture combined with moving cupping and ear point tapping may effectively relieve the skin lesions, but the evidence is limited. Also, young patients usually have no time to see the doctor frequently, thus it's necessary to figure out a better frequency of treating.
Interventions
PROCEDURE3 times per week therapeutic frequency
Participants will receive acupuncture, moving cupping and ear-tapping procedure 3 times per week over the 6 weeks period.
PROCEDURE1 time per week therapeutic frequency
Participants will receive acupuncture, moving cupping and ear-tapping procedure 1 time per week over the 6 weeks period.
Sponsors
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
15 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed as acne vulgaris. * GAGS score between 19 and 38 points. * Age of 15 to 35 years.
Exclusion criteria
* Other types of acne: acne conglobate, acne fulminans，acne medicamentosa, premenstrual acne，cosmetic acne and trade acne. * Presence of any other systemic disease that could affect the acne severity by its presence, such as polycystic ovarian syndrome, or thyroid diseases, or atypical congenital adrenal hyperplasia；or by any medication prescribed for the treatment of the systemic diseases. \-- Use of any topical acne treatment or systemic antibiotics or traditional Chinese medicine within 2 weeks before study initiation. Use of a systemic retinoid within 9 months before study initiation. Use of a systemic steroid within 9 months before study initiation. Presence of any change in the use of oral contraceptive pills or anti-inflammatory drugs within 3 months before study initiation. * Presence of any other skin disease that could interfere with the assessment of the acne, such as folliculitis or rosacea. * Presence of severe heart, liver, kidney or hematopoietic system diseases, as well as severe malnutrition. * Pregnancy or lactation. * Recent use of this research scheme within 4 weeks before study initiation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| IGA success rate | Baseline, week 1-6 | The proportion of subjects who achieved at least a two-point reduction from baseline to week 6 in IGA(Investigator's Global Assessment, scale from 0 to 5) score |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The change of the Visual Analogue Scale (VAS) for facial pruritus from baseline | Baseline, week 6, week 18, week 30 | VAS uses a 100-mm line that is labeled at each end, and 0 mm represents no itch, and 100 mm represents unbearable itch. Patients will rate the VAS (average VAS of facial itch in the past 24 hours), and a researcher will record the VAS once weekly, generally at the third weekly treatment. The mean weekly VAS of itch over weeks 1-6 will be calculated as the sum VAS of each week divided by the number of weeks assessed. |
| The change of the Visual Analogue Scale (VAS) for facial lesion pain from baseline. | Baseline, week 6, week 18, week 30 | Visual Analogue Scale (VAS)VAS uses a 100-mm line that is labeled at each end, and 0 mm represents no pain, and 100 mm represents unbearable pain. Patients will rate the VAS (average VAS of facial pain in the past 24 hours), and a researcher will record the VAS once weekly, generally at the third weekly treatment. The mean weekly VAS of pain over weeks 1-6 will be calculated as the sum VAS of each week divided by the number of weeks assessed. |
| The change of IGA (Investigator's Global Assessment) score from baseline | Baseline, week 6, week 18, week 30 | After 6 weeks treating, the IGA(Investigator's Global Assessment, scale from 0 to 5) score's change from baseline. |
| The change of the Inflammatory Lesions (IN) on the face from baseline. | Baseline, week 6, week 18, week 30 | IN is the sum of papules, pustules, nodules and cysts. |
| The change of the Skindex-16 dermatologic survey score from baseline. | Baseline, week 6, week 18, week 30 | Skindex-16 is a dermatologic quality-of-life survey. There are 16 questions in this survey. It concerns the skin condition which has bothered the patient the most during the past week. This survey calculated from 3 aspects including symptoms, emotions and functions. The score of each question is 0 to 6 points, and multiply by 16.6667，and get the sum of 16 questions' score. The average of the sum of 16 questions' score is the final result of skindex-16 dermatology survey. When the score is higher, it means the disease has greater influence on the patient. |
| The change of the Total Lesion Count (TLC) on the face from baseline. | Baseline, week 6, week 18, week 30 | TLC is the sum of the inflammatory and non-inflammatory counts, including comedones, papules and pustules, nodules and cysts. |
Countries
China
Contacts
Primary ContactChang Xie, Bachelor
Backup ContactZhishun Liu, Doctor
Outcome results
None listed